Exploration of the effect of treatment to progression with the VEGF signaling inhibitor cediranib (CED) plus chemotherapy (CT) on the results of the HORIZON (HZ) II trial in first-line metastatic colorectal cancer.
A. Fielding
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
P. M. Hoff
Consultant or Advisory Role - AstraZeneca
L. Pike
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
D. Wilson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
J. D. Robertson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca